studies

es-BC - TNBC - NA - all population, atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo plus SoC, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpassion-031 (all population), 2020 0.69 [0.25; 1.89] 0.69[0.25; 1.89]IMpassion-031 (all population), 202010%333NAnot evaluable events or deaths (EFS)detailed resultsIMpassion-031 (all population), 2020 0.76 [0.40; 1.44] 0.76[0.40; 1.44]IMpassion-031 (all population), 202010%333NAnot evaluable pCR detailed resultsIMpassion-031 (all population), 2020 1.95 [1.26; 3.01] 1.95[1.26; 3.01]IMpassion-031 (all population), 202010%333NAnot evaluable AE (any grade)detailed resultsIMpassion-031 (all population), 2020 0.49 [0.02; 14.69] 0.49[0.02; 14.69]IMpassion-031 (all population), 202010%331NAnot evaluable AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.10 [0.71; 1.72] 1.10[0.71; 1.72]IMpassion-031 (all population), 202010%331NAnot evaluable AE leading to death (grade 5)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 1.02[0.06; 16.42]IMpassion-031 (all population), 202010%331NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpassion-031 (all population), 2020 1.18 [0.70; 2.01] 1.18[0.70; 2.01]IMpassion-031 (all population), 202010%331NAnot evaluable SAE (any grade)detailed resultsIMpassion-031 (all population), 2020 2.00 [1.20; 3.36] 2.00[1.20; 3.36]IMpassion-031 (all population), 202010%331NAnot evaluable STRAE (any grade)detailed resultsIMpassion-031 (all population), 2020 1.58 [0.91; 2.75] 1.58[0.91; 2.75]IMpassion-031 (all population), 202010%331NAnot evaluable TRAE (any grade)detailed resultsIMpassion-031 (all population), 2020 0.98 [0.14; 7.05] 0.98[0.14; 7.05]IMpassion-031 (all population), 202010%331NAnot evaluable TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.15 [0.74; 1.77] 1.15[0.74; 1.77]IMpassion-031 (all population), 202010%331NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 1.02[0.06; 16.42]IMpassion-031 (all population), 202010%331NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Rash TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.32; 3.23] 1.02[0.32; 3.23]IMpassion-031 (all population), 202010%331NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.21 [0.54; 2.69] 1.21[0.54; 2.69]IMpassion-031 (all population), 202010%331NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.54 [0.25; 9.32] 1.54[0.25; 9.32]IMpassion-031 (all population), 202010%331NAnot evaluable Back pain AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Cough AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 4.15 [0.46; 37.53] 4.15[0.46; 37.53]IMpassion-031 (all population), 202010%331NAnot evaluable Dry skin AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Dyspepsia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.14; 7.32] 1.02[0.14; 7.32]IMpassion-031 (all population), 202010%331NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.23 [0.37; 4.11] 1.23[0.37; 4.11]IMpassion-031 (all population), 202010%331NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.25 [0.61; 2.57] 1.25[0.61; 2.57]IMpassion-031 (all population), 202010%331NAnot evaluable Headache AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.84 [0.35; 2.00] 0.84[0.35; 2.00]IMpassion-031 (all population), 202010%331NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.44 [0.62; 9.59] 2.44[0.62; 9.59]IMpassion-031 (all population), 202010%331NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.91 [0.36; 2.30] 0.91[0.36; 2.30]IMpassion-031 (all population), 202010%331NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 1.02[0.06; 16.42]IMpassion-031 (all population), 202010%331NAnot evaluable Lacrimation increased AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.86 [0.76; 4.55] 1.86[0.76; 4.55]IMpassion-031 (all population), 202010%331NAnot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Myalgia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.28 [0.06; 1.38] 0.28[0.06; 1.38]IMpassion-031 (all population), 202010%331NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.10 [0.65; 1.84] 1.10[0.65; 1.84]IMpassion-031 (all population), 202010%331NAnot evaluable Oropharyngeal pain AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Paraesthesia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.40 [0.08; 2.09] 0.40[0.08; 2.09]IMpassion-031 (all population), 202010%331NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.28 [0.34; 4.86] 1.28[0.34; 4.86]IMpassion-031 (all population), 202010%331NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.25 [0.03; 2.26] 0.25[0.03; 2.26]IMpassion-031 (all population), 202010%331NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 4.11 [0.18; 91.86] 4.11[0.18; 91.86]IMpassion-031 (all population), 202010%331NAnot evaluable Rash AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 4.15 [0.46; 37.53] 4.15[0.46; 37.53]IMpassion-031 (all population), 202010%331NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 6.20 [0.31; 124.85] 6.20[0.31; 124.85]IMpassion-031 (all population), 202010%331NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.05 [0.18; 22.82] 2.05[0.18; 22.82]IMpassion-031 (all population), 202010%331NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-11-05 18:27 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 305 - treatments: 1282

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons